SNCA, synuclein alpha, 6622

N. diseases: 449; N. variants: 66
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 AlteredExpression disease BEFREE Interestingly, both PD and incidental Lewy body disease tissues showed 100% concordance for elevated levels of pathological α-synuclein seeding activity compared to control tissues. 31758740 2020
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE This study highlights the therapeutic potential of α-synuclein immunotherapy for the treatment of PD and DLB, and provides a framework for screening of α-synuclein antibodies to identify those with preferred properties. 31837422 2020
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE They expressed truncated, oligomeric and proteinase K-resistant phosphorylated forms of α-synuclein in the regions that are specifically affected in Parkinson's disease and/or dementia with Lewy bodies, including the olfactory bulb, cerebral cortex, striatum and substantia nigra. 31816026 2020
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE α-Synuclein (α-Syn) is a key pathogenic protein in α-synucleinopathies including Parkinson disease and dementia with Lewy bodies. 31734439 2020
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE One of the pathological proteins, alpha-synuclein (α-syn), accumulates in the brains of Parkinson disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA), which are designated as synucleinopathies. 31785806 2020
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE PD, PD with dementia, and dementia with Lewy bodies are clinical syndromes characterized by the neuropathological accumulation of alpha-synuclein in the CNS that represent a clinicopathological spectrum known as Lewy body disorders. 31660655 2020
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE Our study suggests that catD upregulation may be an adaptive response to AD-related processes leading to neurofibrillary degeneration, but may not be directly associated with formation of α-synuclein inclusions in Lewy body dementia. 30051532 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE The patients with Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies whose brain pathology indicated deposit of alpha-synuclein along with the co-occurrence of tau pathology and amyloid-beta plaques presented LRP10 mutations. 31582232 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 AlteredExpression disease BEFREE Although the mechanisms through which glucocerebrosidase regulates the homeostasis of α-synuclein remains poorly understood, the identification of reduced glucocerebrosidase activity in the brains of patients with PD and dementia with Lewy bodies has paved the way for the development of novel therapeutic strategies directed at enhancing glucocerebrosidase activity and reducing α-synuclein burden, thereby slowing down or even preventing neuronal death. 30589955 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 GeneticVariation disease BEFREE Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile. 31189032 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE α-Synuclein is the most thoroughly investigated because of its close association with Parkinson's disease (PD), dementia with Lewy bodies and multiple system atrophy. 30650656 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE Alpha-synuclein (αS) is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). 31331359 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE The pathology finding in DLB is misfolded alpha-synuclein, the main component of Lewy bodies, propagating in the central nervous system. 30807982 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 GeneticVariation disease BEFREE Adult-onset neurodegenerative disorders, like Parkinson's disease (PD) and dementia with Lewy bodies (DLB), that share the accumulation of aggregated α-synuclein (αSyn<sub>agg</sub>) as their hallmark molecular pathology are collectively known as α-synucleinopathies. 30706414 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE Emerging evidence implicates α-synuclein oligomers as potential culprits in the pathogenesis of Lewy body disease (LBD). 31685859 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE Interestingly, there was a high concentration of αSyn aggregates in the stratum lacunosum moleculare of hippocampal CA2 region, which has been associated in humans with accumulation of αSyn pathology and neural atrophy in dementia with Lewy bodies. 31175983 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE Moreover, tau and α-synuclein concentrations showed opposite trends in AD and DLB patients, suggesting the benefit of combining the two biomarkers for differentiation of DLB from AD and controls. 31553333 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE Two agents targeting alpha-synuclein (NPT200-11 and ambroxol) currently hold promise as disease-modifying therapies for DLB, but they are yet to be tested in clinical trials. 30680679 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE The group of neurodegenerative diseases, Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) all exhibit inclusions containing amyloid-type α-synuclein (α-syn) aggregates within degenerating brain cells. 31603909 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE Cortical overexpression of human α-synuclein is not sufficient to produce cognitive dysfunction, whereas combining this overexpression with fibril seeds yields both cognitive and histopathological phenotypes that are relevant to human Lewy body disease. 31449702 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE α-Synuclein is the major component of Lewy bodies and a candidate biomarker for neurodegenerative diseases in which Lewy bodies are common, including Parkinson's disease and dementia with Lewy bodies. 30125936 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE It has been suggested that α-synuclein (α-syn), a major component of Lewy bodies, is related to the onset and progression of DLB. 30503177 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE A number of studies using postmortem brain samples showed that the deposition of protein aggregates of α-synuclein, termed Lewy bodies, is evident in multiple brain regions of patients from PD and dementia with Lewy bodies (DLB). 30761004 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE Alpha-synuclein (α-Syn) forms aggregates mainly in neurons in PD and DLB, while oligodendroglial α-Syn aggregates are characteristic of MSA. 31504665 2019
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease
0.800 Biomarker disease BEFREE Multiple system atrophy and dementia with Lewy bodies are other neurodegenerative diseases in which α-synuclein aggregates are the main pathological characteristic. 30341610 2019